Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02989610) enrolled 234 participants, all of whom received a type of brain stimulation treatment for Parkinson's disease. The study compared two different ways of delivering that stimulation: an "omnidirectional" approach (where the signal spreads out equally in all directions) and a "directional" approach (where the signal is steered in a specific direction). Of the 234 people who started the trial, 184 completed it, and 50 did not finish. The trial was measuring something called the "therapeutic window" — that is, the range of stimulation strength that eases symptoms without causing unwanted side effects — to see whether one approach produced a wider window than the other. The reported data shows that 185 participants were included in the main analysis looking at whether directional stimulation produced a wider therapeutic window compared to a pre-set benchmark of 60%. The same group of 185 participants was also used for a related secondary analysis, which used a slightly different statistical benchmark. However, the actual percentage figures for how many participants had a wider therapeutic window under directional versus omnidirectional stimulation were not reported in the data submitted to ClinicalTrials.gov, so those specific numbers cannot be described here. For a separate secondary measure, the trial tracked changes in a Parkinson's motor symptom rating scale (scored 0–108, where higher numbers mean more severe symptoms). The reported data shows an average change of 25.1 points when participants were using the omnidirectional approach at 3 months, and 30.8 points when using the directional approach at 6 months — both measured while participants were on their regular Parkinson's medication. It is worth noting that because these two measurements were taken at different time points and under different conditions, a direct comparison between the two numbers requires careful interpretation by a medical professional. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Parkinson's Disease Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are able to give your own consent to take part in the study
- You have been diagnosed with Parkinson's disease and your doctor has recommended you receive, or you have already received, a specific type of deep brain stimulation (DBS) device called the Infinity system, with leads placed on both sides of a specific area of the brain (called the Subthalamic Nucleus)
- You are able to attend the required follow-up appointments during the study
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You are not considered a suitable candidate for surgery
- In the opinion of the study doctor, you would not be able to handle having multiple device programming sessions in a single visit
- You are unable to follow the required schedule of check-up appointments during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 3 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Percentage Of Participants With Wider Therapeutic Window With Directional Programming (Superiority)
Other options
Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.